INFORMATI	ON
DISCLOSUI	RE
DISCLOSUI STATEMEN	T

 Atty. Docket No.: 275.0009 0101
 Serial No.: 10/780,150

 Applicant(s): MUNN et al.
 Confirmation No.: 1273

 Application Filing Date: 02/17/04
 Group: 1645 [6/4]

2 0 2004 3

Information Disclosure Statement mailed:

U.S. PATENT DOCUMENTS

Examiner Initial			Name	Class	Subclass	Filing Date If
/ZV/	5,478,556	12/26/95	Elliott et al.			
	5,837,231	11/17/98	Low et al.			
	5,861,159	01/19/99	Pardoll et al.			
	6,251,399	06/26/01	Diamond et al.			
	6,395,876 B1	05/28/02	Munn et al.			
	6,451,840	09/17/02	Munn et al.			
	6,482,416 .	11/19/02	Munn et al.			
	2002 0155104 A1	10/24/02	Munn et al.			
V	2002 0114784 A1	08/22/02	Li et al.			

FOREIGN PATENT DOCUMENTS

Examiner	Сору	Document Number	Date	Country	Class	Subclass	Trans	lation
Initial	Enclosed						Yes	No
/ZV/	V	99/29852	06/17/99	wo				
IZVÍ	V	99/29310	06/17/99	WO				

Examiner Initial	Copy Enclosed	Document Description
IZVI	•	Alberti-Giani, "Regulation of the Kynurenine Metabolic Pathway by Interferon-γ in Murine Cloned Macrophages and Microglial Cells," <i>J. Neurochem</i> , 1996;66:996-1004.
NOD Islets Prolongs Graft Survival After Adoptive Transfer of Diabetogeni Splenocytes," <i>Diabetes</i> , 2002;51:356-365.		Alexander et al., "Indoleamine 2,3-Dioxygenase Expression in Transplanted NOD Islets Prolongs Graft Survival After Adoptive Transfer of Diabetogenic Splenocytes," <i>Diabetes</i> , 2002;51:356-365.
		Almand et al., "Clinical Significance of Defective Dendritic Cell Differentiation in Cancer," Clin. Cancer Res., 2000;6:1755-1766.
IZVI	~	Asselin-Paturel et al., "Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology," <i>Nat. Immunol.</i> , 2001;2:1144-1150.

EXAMINER	Date Considered
/Zohreh Vakili/ (06/13/2007)	/Zohreh Vakili/ (06/13/2007)

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	1 uge 2 0) 19
Atty. Docket No.: 275.0009 0101	Serial No.: 10/780,150
Applicant(s): MUNN et al.	Confirmation No.: 1273
Application Filing Date: 02/17/04	Group: 1645 1614
Information Disclosure Statement mailed:	

Examiner Initial		Copy Enclosed	Document Description
/ZV/		V	Aune et al., "Inhibition of Tumor Cell Growth by Interferon-γ Is Mediated by Two Distinct Mechanisms Dependent upon Oxygen Tension: Induction of Tryptophan Degradation and Depletion of Intracellular Nicotinamide Adenine Dinucleotide," J Clin Invest, 1989;84:863-875.
		/	Azuma, et al., "B70 antigen is a second ligand for CTLA-4 and CD28," <i>Nature</i> 1993;366:76-79.
		V	Ben-Efraim, "Immunomodulating Anticancer Alkylating Drugs: Targets and Mechanisms of Activity," Current Drug Targets, 2001;2:197-212.
V		V	Benson et al., "T-cell activation and receptor downmodulation precede deletion induced by mucosally administered antigen," <i>J. Clin. Invest.</i> , 2000;106:1031-1038.
			Bjorck et al., "Cutting Edge: CD19+ Pro-B Cells Can Give Rise to Dendritic Cells In Vitro," J. Immunol., 1998;161:5795-5799.
	•		Borrello et al., "A Universal Granulocyte-Macrophage Colony-Stimulating Factor-Producing Bystander Cell Line for Use in the Formulation of Autologous Tumor Cell-Based Vaccine," <i>Hum. Gene. Ther.</i> , 1999;10:1983-1991.
			Bronte et al., "Unopposed Production of Granulocyte-Macrophage Colony-Stimulating Factor by Tumors Inhibits CD8+ T Cell Responses by Dysregulating Antigen-Presenting Cell Maturation," <i>J. Immunol.</i> , 1999;162:5728-5737.
		>	Carlin et al., "Intrferon-Induced Indoleamine 2,3-Dioxygenase Activity in Human Mononuclear Phagocytes," J. Leuk. Biol. 1989;45:29-34.
		V	Cella et al., "Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon," <i>Nat. Med.</i> , 1999;5:919-923.
V		V	Chambers, "The expanding world of co-stimulation: the two-signal model revisited," <i>Trend Immunol</i> . 2001;22:217-223.
		V	Chen et al., "The Role of Tumor Necrosis Factor α in Modulating the Quantity of Peripheral Blood-Derived, Cytokine-Driven Human Dendritic Cells and Its Role in Enhancing the Quality of Dendritic Cell Function in Presenting Soluble Antigens to CD4+ T Cells in Vitro," <i>Blood</i> , 1998;91:4652-4661.

EXAMINER	Date Considered		
/Zohreh Vakili/ (06/13/2007)	/Zohreh Vakili/ (06/13/2007)		

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	145620)14
Atty. Docket No.: 275.0009 0101	Serial No.: 10/780,150
Applicant(s): MUNN et al.	Confirmation No.: 1273
Application Filing Date: 02/17/04	Group: 1643 1614
Information Disclosure Statement mailed:	

Examiner Initial	Copy Enclosed	Document Description
IZVI	>	Chon, "Cooperative Role of Interferon Regulatory Factor 1 and p91 (STAT1) Response Elements in Interferon-γ-inducible Expression of Human Indoleamine 2,3-Dioxygenase Gene," <i>J Biol Chem</i> , 1996;271:17247-17252.
IZVI	Cochran et al., "Sentinel Lymph Nodes Show Profound Downregulation Antigen-Presenting Cells of the Pracortex: Implications for Tumor Biolo Treatment," <i>Mod. Pathol.</i> , 2001;14:604-608.	
IZVI	V	Colasante et al., "Role of Cytokines in Distribution and Differentiation of Dendritic Cell/Langerhans' Cell Lineage in Human Primary Carcinomas of the Lung," <i>Hum. Pathol.</i> , 1995;26:866-872.
IZVI	•	Corbett et al., "Response of Transplantable Tumors of Mice to Anthracenedione Derivatives Alone and in Combination with Clinically Useful Agents," Cancer Treatment Reports, 1982;66:1187-1200.
/ZV/	V	Corcoran et al.,"The lumphoid Past of Mouse Plasmacytoid Cells and Thymic Dendritic Cells," <i>J. of Immunology</i> , 2003;170:4926-4932.
IZVI	•	Cuenca et al., "Extra-Lymphatic Solid Tumor Growth Is Not Immunologically Ignored and Results in Early Induction of Antigen-Specific T-Cell Anergy: Dominant Role of Cross-Tolerance to Tumor Antigens," Cancer Res., 2003;63:9007-9015.
IZVI	Curreli et al., "Human Primary CD4+ T Cells Activated in the Proα2b Express Functional Indoleamine 2,3-Dioxygenase," J. Interferences., 2001;21:431-437.	
IZVI	Dai et al., "Molecular Clong, sequencing and expression of human interfero gamma-inducible indoleamine 2,3-dioxygenase cDNA," <i>Biochem. Biophys. Commun.</i> , 1990;168:1-8 GenBank Accession Number M34455.	
IZVI	Daubener, "Establishment of T-helper type 1- and T-helper type 2-like huma Toxoplasma antigen-specific T-cell clones," Immunol. 1995;86:79-84.	
IZVI	~	Daubener, et al., "Anti-parasitic effector mechanisms in human brain tumor cells: role of interferon-γ and tumor necrosis factor-α," Eur. J. Immunol. 1996;26:487-492.
IZVI	V	Dranoff, "GM-CSF-based cancer vaccines," Immunol. Rev. 2002;188:147-154.

EXAMINER	Date Considered
/Zohreh Vakili/ (06/13/2007)	/Zohreh Vakili/ (06/13/2007)

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	7 45 5 7 7 7 7
Atty. Docket No.: 275.0009 0101	Serial No.: 10/780,150
Applicant(s): MUNN et al.	Confirmation No.: 1273
Application Filing Date: 02/17/04	Group: 1645 1614
Information Disclosure Statement mailed:	

Examiner Initial	Copy Enclosed	Document Description
IZVI	V	Dranoff et al., "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity," <i>Proc. Natl. Acad. Sci.</i> USA, 1993;90:3539-3543.
IZVI	V	Dudley et al., "Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes," <i>Science</i> , 2002;298:850-854. Supplemental On-line Material can be retrieved from www.sciencemag.org/cqi/content/full/1076514/DC1
IZVI	•	Dzionek et al., "BDCA-2, BDCA-3, and BDCA-4: Three Markers for Distinct Subsets of Dendritic Cells in Human Peripheral Blood," <i>J Immunol.</i> , 2000;165:6037-6046.
IZVI	V	Fallarino et al., "Functional expression of indoleamine 2,3-dioxygenase by murine CD8α+ dendritic cells," <i>Int. Immunol.</i> , 2002;14:65-68.
/ZV/	/	Fallarino et al., "Modulation of tryptophan catabolism by regulator T cells," <i>Nat. Immunol.</i> , 2003;4:1206-1212. Epub 2003, Oct. 26.
IZVI	/	Fearon et al., The Instructive Role of Innate Immunity in the Acquired Immune Response," Science 1996;272:50-54.
IZVI	V	Fearon et al., "Regulation of B Lymphocyte Responses to Foreign and Self-Antigens by the CD19/CD21 Complex," Ann. Rev. Immunol., 2000;18:393-422.
IZVI	V	Feng et al., "Interferon γ-resistant mutants are defective in the induction of indoleamine 2,3-dioxygenase," <i>Proc. Natl. Acad. Sci.</i> , USA, 1989;86:7144-7148.
/ZV/	V	Friberg et al., "Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell mediated rejection," <i>Intl J of Cancer</i> , 2002;101:151-155.
IZVI	V	Grant et al., "Induction of Indolamine 2,3-Dioxygenase in Primary Human Macrophages by Human Immunodeficiency Virus Type 1 Is Strain Dependent," J. Virol., 2000;74:4110-4115.
IZVI	V	Grohmann et al., "IFN-γ Inhibits Presentation of a Tumor/Self Peptide by CD8α Dendritic Cells Via Potentiation of the CD8α Subset ¹ ," J. Immunol., 2000;165:1357-1363.
IZVI	~	Grohmann et al., "CD40 Ligation Ablates the Tolerogenic Potential of Lymphoid Dendritic Cells ¹ ," <i>J. Immunol.</i> 2001;166:277-283.

EXAMINER	Date Considered	
/Zohreh Vakili/ (06/13/2007)	/Zohreh Vakili/ (06/13/2007)	
#Examination to the Heather than the state of the state o		

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT

Atty. Docket No.: 275.0009 0101

Applicant(s): MUNN et al.

Application Filing Date: 02/17/04

Information Disclosure Statement mailed:

Serial No.: 10/780,150

Confirmation No.: 1273

Group: 1645 1614

Examiner Initial	Copy Enclosed	Document Description	
IZVI	V	Grohmann et al., "IL-6 Inhibits the Tolerogenic Function of CD8α ⁺ Dendritic Cells expressing Indoleamine 2,3-Dioxygenase ¹ ," J. Immunol. 2001;167:708-714.	
IZVI	<i>'</i>	Grohmann et al., "CTLA-4-lg regulates tryptophan catabolism in vivo," Nature Immunology 2002;3:1097-1101.	
IZVI	✓	Grohmann et al., "CTLA-4-Ig regulates tryptophan catabolism in vivo," 2002 Nature Publishing Group. Available at http://www.nature.com/natureimmunology Advance online publication. pp. 1-5	
IZVI	V	Grohmann et al., "Tolerance, Dcs and tryptophan: much ado about IDO," <i>Trends in Immunology</i> 2003;24:242-248.	
IZVI	V	Grohmann et al., "A Defect in Tryptophan Catabolism Impairs Tolerance in Nonobese Diabetic Mice," <i>J. Exp. Med.</i> 2003;198:153-160.	
IZVI	•	Gupta, "Antiparasitic and Antiproliferative Effects of Indoleamine 2,3-Dioxygenase Enzyme Expression in Human Fibroblasts," <i>Infect. Immun.</i> 1994; 62:2277-2284.	
IZVI	•	Hashimoto et al., "Determination of free amino acid enantiomers in rat brain and serum by high-performance liquid chromatography after derivatization with N-tertbutyloxycarbonyl-L-cysteine and o-phthaldialdehyde," J. Chromatography 1992;582:41-48.	
IZVI	~	Hawiger et al., "Dendritic Cells Induce Peripheral T Cell Unresponsiveness Under Steady State Conditions in Vivo," <i>J. Exp. Med.</i> , 2001;194:769-779.	
IZVI	V	Huang et al., "Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens," Science, 1994;264:961-965.	
IZVI	V	Hwu et al., "Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation," <i>J. Immunol.</i> 2000;164:3596-3599.	
IZVI	~	Izon et al., "A Common Pathway for Dendritic Cell and Early B Cell Development," <i>J. Immunol.</i> , 2001;167:1387-1392.	
IZVI	V	Jonuleit et al., "Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions," <i>Eur. J. Immunol.</i> , 1997;27:3135-3142.	

EXAMINER D	Pate Considered
/Zohreh Vakili/ (06/13/2007)	/Zohreh Vakili/ (06/13/2007)

OMB No. 0651-0011 Page 6 of 14

_		1 250 00 1 1 1
	Atty. Docket No.: 275.0009 0101	Serial No.: 10/780,150
	Applicant(s): MUNN et al.	Confirmation No.: 1273
	Application Filing Date: 02/17/04	Group: 1645 1614
	Information Disclosure Statement mailed:	

Examiner Initial	Copy Enclosed	Document Description
IZVI	•	Kamimura et al., "Localization and Developmental Change of Indoleamine 2,3-Dioxygenase Activity in the Human Placenta," <i>Acta. Med.</i> Okayama, 1991;45:135-139.
IZVI	~	Karsunky et al., "Flt3 Ligand Regulates Dendritic Cell Development from Flt3 ⁺ Lymphoid and Myeloid-committed Progenitors to Flt3 ⁺ Dendritic Cells In Vivo," <i>J. Exp. Med.</i> , 2003;198:305.
IZVI	V	Koide, "The Signal Transduction Mechanism Responsible for Gamma Interferon-Induced Indoleamine 2,3-Dioxygenase Gene Expression," <i>Infect. Immun</i> . 1994;62:948-955.
/ZV/	V	Konan, "Importance of the Two Interferon-stimulated Response Element (ISRE) Sequences in the Regulation of the Human Indoleamine 2,3-Dioxygenase Gene," <i>J Biol Chem</i> , 1996;271:19140-19145.
IZVI	V	Konieczny et al., "IFN-γ Is Critical for Long-Term Allograft Survival Induced by Blocking the CD28 and CD40 Ligand T Cell Costimulation Pathways ¹ ," <i>J. Immunol.</i> , 1998;160:2059.
IZVI	V	Kotera et al., "Comparative Analysis of Necrotic and Apoptotic Tumor Cells As a Source of Antigen(s) in Dendritic Cell-based Immunization," Cancer Research 2001;61(22):8105-8109.
IZVI	V	Kudo et al., "Human placental indoleamine 2,3-dioxygenase: cellular localization and characterization of an enzyme preventing fetal rejection," <i>Biochem. Biophys. Acta</i> , 2000;1500:119-124.
IZVI	V	Lee et al., "Pattern of Recruitment of Immunoregulatory Antigen-Presenting Cells in Malignant Melanoma," <i>Laboratory Investigation</i> , 2003;83:1457-1466.
IZVI .	V	Lee et al., "Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division," <i>Immunology</i> 2002;107:452-460.
/ZV/	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Logan et al., "HeLa cells cocultured with peripheral blood lymphocytes acquire an immuno-inhibitory phenotype through up-regulation of indoleamine 2,3-dioxygenase activity," <i>Immunol.</i> , 2002;105:478.
IZVI	~	Mackensen, et al., "Delineation of the Dendritic Cell Lineage by Generating Large Numbers of Birbeck Granule-Positive Langerhans Cells from Human Peripheral Blood Progenitor Cells in Vitro," <i>Blood</i> 1995;86:2699-2707.

EXAMINER	Date Considered
/Zohreh Vakili/ (06/13/2007)	/Zohreh Vakili/ (06/13/2007)
	A LI MANUN COO D

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT

Atty. Docket No.: 275.0009 0101	Serial No.: 10/780,150
Applicant(s): MUNN et al.	Confirmation No.: 1273
Application Filing Date: 02/17/04	Group: 1645 1614
Information Disclosure Statement mailed:	•

Examiner Initial	Copy Enclosed	Document Description	
IZVI	V	Manegold et al., "Gemcitabine in non-small cell lung cancer (NSCLC)", Invest New Drugs. 2000;18(1):29-42.	
/ZV/	V	•	f a new subpopulation of mouse CD8α ⁺ B220 ⁺ 1 interferon production capacity and 02;100:383-390.
/ZV/	V		kine/Growth Factors and Their Receptors in tes," Int. J. Cancer, 1994;56:853-857.
/ZVI	V		uman spleen dendritic cell phenotype and vivo actibation in a subset of organ donors,"
IZVI	/		and Endocrinological Problems Raised by the rates," Symp. Soc. Exp. Biol. 1953;7:320-388.
IZVI	V	Mellor et al., "Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses," <i>J Immunol.</i> , 2002;168:3771-3776.	
/ZV/	V	Mellor et al., "Cutting Edge: Induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion," <i>J Immunol</i> , 2003;171:1652-1655.	
IZVI	V .	Mellor et al., "Prevention of T cell-driven complement activation and inflammation by Tryptophan catabolism during pregnancy," <i>Nature Immunol</i> 2001;2:64-68.	
IZVI	V	Mellor et al., "Indoleamine 2,3-dioxygenase, immunosuppression and pregnancy," J. Reprod. Immunol. 2002;57:143-150.	
IZVI	V	Mellor et al., "Tryptophan catabolism and regulation of adaptive immunity," J. Immunol. 2003;170:5809-5813.	
/ZV/	>	Mellor et al., "Tryptophan catabolism and T cell tolerance: immunosuppression by starvation?," <i>Immunol. Today</i> 1999;20:469-473.	
/ZV/	>	Miki et al., "Blockade of Tryptophan Catabolism Prevents Spontaneous Tolerogenicity of Liver Allografts" <i>Transplantation Proceedings</i> 2001;33:129-130.	
/ZV/ ·	V	Mikkola et al., "Reversion of B Cell Commitment Upon Loss of Pax5 Expression," Science, 2002;297:110-113.	
EXAMI	NER		Date Considered
/Zoh	reh Vakil	i/ (06/13/2007)	/Zohreh Vakili/ (06/13/2007)

OMB No. 0651-0011 Page 8 of 14

	Atty. Docket No.: 275.0009 0101	Serial No.: 10/780,150	
	Applicant(s): MUNN et al.	Confirmation No.: 1273	
	Application Filing Date: 02/17/04	Group: 1645 1614	
ſ	Information Disclosure Statement mailed:		

Examiner Initial	Copy Enclosed	Document Description	
IZVI	>	Moffett et al., "Antibodies to quinolinic acid and the determination of its cellular distribution within the rat immune system," Cell Tissue Res, 1994;278:461-469.	
IZVI	>	Mondino, et al., "The anatomy of T-cell activation and tolerance," <i>Proc. Natl. Acad. Sci</i> USA 1996;93:2245-2252.	
. IZVI	V	Morahan, et al., In: Heppner GA, Fulton AM, eds. Macrophages and Cancer, Boca Raton, FL: CRC Press 1988:1-25.	
:/ZV/	V	Moser, "Dendritic Cells in Immunity and Tolerance - Do They Display Opposite Functions?" <i>Immunity</i> , 2003;19:5-8.	
/ZV/	V	Munn, "Cytokine Regulation of Human Monocyte Differentiation in Vitro: The Tumor-Cytotoxic Phenotype Induced by Macrophage Colony-Stimulating Factor is Developmentally Regulated by γ-Interferon," Cancer Res. 1993;53:2603-2613.	
/ZV/	V	Munn et al., "Selective Activation-Induced Apoptosis of Peripheral T Cells Imposed by Macrophages," J. Immunol., 1996;156:523-532.	
IZVI	V	Munn et al., "Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism," Science 1998; 281:1191-1193.	
/ZV/	V.	Munn et al., "Inhibition of T cell proliferation by macrophage tryptophan catabolism,", <i>J Exp Med</i> , 1999;189:1363-1372.	
IZVI	V	Munn et al., "Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase," <i>Science</i> , 2002;297:1867-1870. Supporting On-Line Material available at www.sciencemag.org/cgi/data/297/5588/1867/DC1/1	
/ZV/	. •	Munn, "Selecting the right dentritic cell subset," Lecture Presented January 31, 2003 at Tandem BMT Meetings at Keystone. January 30-February 3, 2003, 57 pages.	
IZVI	Munn et al., "Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes," J. Clin Invest 2004;114:280-29		
IZVI	~	Munn et al., "IDO and tolerance to tumors," Trends Molec Med. 2004;10:15-18.	
IZVI	~	Musso, "Interleukin-r Inhibits Indoleamine 2,3-Dioxygenase Expression in Human Monocytes," <i>Blood</i> 1994; 83:1408-1411.	

EXAMINER	Date Considered	
/Zohreh Vakili/ (06/13/2007)	/Zohreh Vakili/ (06/13/2007)	
/Zohreh Vakili/ (06/13/2007)	/Zonien vakiii/ (00/13/2007)	

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OMB No. 0651-0011
Page 9 of 14

INFORMATION DISCLOSURE STATEMENT

Atty. Docket No.: 275.0009 0101	Serial No.: 10/780,150
Applicant(s): MUNN et al.	Confirmation No.: 1273
Application Filing Date: 02/17/04	Group: 1645 1614
Information Disclosure Statement mailed	d:

Examiner Initial	Copy Enclosed	Document Description	
IZVI	V	Nagineni, "Mechanisms of Interferon-Induced Inhibition of <i>Toxoplasma gondii</i> Replication in Human retinal Pigment Epithelial Cells," <i>Infect. Immun.</i> 1996;64 (10):4188-4196.	
IZVI	/	Nguyen et al., "Tumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without Tolerance," <i>J. Exp. Med.</i> , 2002;195:423-435.	
/ZV/	V	Nossal, "Negative Selection of Lymphocytes," Cell 1994;76:229-239.	
IZVI	V	Nowak et al., "Synergy between Chemotherapy and Immunotherapy in the Treatment of Established Murine Solid Tumors," Cancer Research 2003;63: 4490-4496.	
IZVI	V	Nutt et al., "Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments," <i>EMBO J.</i> , 1998;17:2319-2333.	
IZVÍ	V	Nutt et al., "Committment to the B-lymphoid lineage depends on the transcription factor Pax5," <i>Nature</i> , 1999;401:556-562.	
IZVI	V	Oettle, et al., "Phase I Trial of gemcitabine (Gemzar(, 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer", <i>Anticancer Drugs</i> , 1999;10(8):699-704.	
/ZV/	~	O'Keefe et al., "Mouse Plasmacytoid Cells: Long-lived Cells, Heterogeneous in Surface Phenotype and Function, that Differentiate Into CD8 ⁺ Dendritic Cells Only after Microbial Stimulus," <i>J. Exp. Med.</i> , 2002;196:1307-1319.	
IZVI	V	Orenstein et al., "The Macrophage Origin of the HIV-Expressing Multinucleated Giant Cells in Hyperplastic Tonsils and Adenoids," <i>Ultrastruct. Pathol.</i> , 1999;23:79-91.	
/ZV/	V	Orlando et al., "Gemcitabine in ovarian cancer", Semin Oncol. 2001 June;28(3 Suppl 10):62-69.	
/ZV/	V	Pardoll, "Does the Immune System See Tumors as Foreign or Self?," Ann. Rev. Immunol, 2003;21:807-839.	
IZVI	•	Pfefferkorn, "Interferon γ blocks the growth of <i>Toxoplasma gondii</i> in human fibroblasts by inducing the host cells to degrade tryptophan," <i>Proc. Natl. Acad. Sci.</i> USA 1984;81:908-912.	

EXAMINER	•	Date Considered
/Zohreh Vakili/ (06/13/2007)	,	/Zohreh Vakili/ (06/13/2007)
		formand with NARED (00. D time through situation if not in

OMB No. 0651-0011 Page 10 of 14

Atty. Docket No.: 275.0009 0101		Serial No.: 10/780,150	
	Applicant(s): MUNN et al.	Confirmation No.: 1273	
	Application Filing Date: 02/17/04	Group: 1645 1614	
	Information Disclosure Statement mailed:		

Examiner Initial	Copy Enclosed	Document Description	
IZVI	>	Probst et al., "Inducible Transgenic Mice Reveal Resting Dendritic Cells as Potent Inducers of CD8 ⁺ T Cell Tolerance," <i>Immunity</i> , 2003;18:713-720.	
IZVI	>	Quill, "Anergy as a Mechanism of Peripheral T Cell Tolerance," <i>J. Immunol</i> . 1996;156:1325-1327.	
/ZV/	V	Reddy et al., "A Monocyte Conditioned Medium Is More Effective Than Defined Cytokines in Mediating the Terminal Maturation of Human Dendritic Cells," <i>Blood</i> , 1997:90:3640-3646.	
IZVI	V	Report on the Rare Diseases Research Activities at the National Institutes of Health FY 2003. NSC Number 721782 (Group 2A, pg. 13). 17 pages. Retrieved from the Internet on 07/29/04 at http://rarediseases.info.nih.gov/html/reports/fy2003/nci.html	
IZVI	>	Restito et al., "Basic Aspects of Tumor Immunology," #346 Keystone Symposia 2003 Abstract Book. Abstract/Poster. Keystone, Colorado, February 17-23, 2003. Meetings on Biomedical and Life Sciences that Encourage Scientific Information Exchange and Networking.	
IZVI	/	Ridgway, "The First 1000 Dendritic Cell Vaccinees," Cancer Invest. 2003;21(6):873-886.	
IZVI	V	Rissoan et al., "Subtractive hybridization reveals the expression of mmunoglobulinlike transcript 7, Eph-B1, granzyme B, and 3 novel transcripts in numan plasmacytoid dendritic cells," <i>Blood</i> , 2002;100:3295-3303.	
IZVI	>	Romani et al., "Generation of mature dendritic cells from human blood: An improved method with special regard to clinical applicability," <i>J. Immunol. Methods</i> , 1996;196:137-151.	
IZVI	/	Rosenzwajg, et al.,"Human Dendritic Cell Differentiation Pathway from CD34 ⁺ Hematopoietic Precursor Cells," <i>Blood</i> 1996;87:535-544.	
IZVI	>	Sallusto et al., "Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells is Maintained by Granulocyte/Macrophage Colony-stimulating Factor Plus Interleukin 4 and Downregulated by Tumor Necrosis Factor α," <i>J. Exp. Med.</i> , 1994;179:1109-1118.	
IZVI	V	Sardar, "Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associate dementia," <i>Neurosci Let</i> , 1995;187:9-12.	

EXAMINER	Date Considered
/Zohreh Vakili/ (06/13/2007)	/Zohreh Vakili/ (06/13/2007)

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OMB No. 0651-0011 Page 11 of 14

Atty. Docket No.: 275.0009 0101	Serial No.: 10/780,150
Applicant(s): MUNN et al.	Confirmation No.: 1273
Application Filing Date: 02/17/04	Group: 1645 1614
Information Disclosure Statement mailed	d:

Examiner Initial	Copy Enclosed	Document Description	
IZVI	V	Shortman et al., "Immunity or tolerance? That is the question for dendritic cells," <i>Nature Immunol</i> . 2001;2:988-989.	
IZVI	>	Shurin et al., "FLT3 Ligand Induces the Generation of Functionally Active Dendritic Cells in Mice," Cell Immunol. 1997;179:174-184.	
IZVI	V	Smith et al., "The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1α, IL-6, GM-CSF, and KC," Clin. Exp. Metastasis, 1998;16:655-664.	
IZVI	>	Smyth et al., "A Fresh look at tumor immunosurveillance and immunotherapy," Nat. Immunol., 2001;2:293-299.	
IZVI	>	Sotomayor et al., "Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression," <i>Blood</i> , 2001;98,1070-1077.	
IZVI	V	Southan et al., "Structural Requirements of the Competitive Binding Site of Recombinant Human Indoleamine 2,3-Dioxygenase," <i>Med. Chem. Res.</i> , 1996;343-352.	
IZVI	V	Speiser et al., "Self Antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy," <i>J. Exp. Med.</i> , 1997;186:645-653.	
IZVI	V	Springer et al., "Traffic Signals for Lymphocyte Recirculation and Leukocyte Emigration: The Multistep Paradigm," Cell 1994;76:301-314.	
IZVI	>	Staveley-O'Carroll et al., "Induction of antigen-specific T cell anergy: an early event in the course of tumor progression," <i>Proc. Natl. Acad. Sci.</i> USA, 1998;95:1178-1183.	
IZVI	V	Steinbrink et al., "Induction of Tolerance by IL-10-Treated Dendritic Cells ¹ ," J. Immunol., 1997;159:4772-4780.	
IZVI		Steinman, "Escape from "Horror Autotoxicus": Pathogenesis and Treatment of Autoimmune Disease," Cell 1995;80:7-10.	
İZVI	V	Steinman et al., "The Endocytic Activity of Dendritic Cells," Exp. Med. 1995;182:283-288.	

EXAMINER	Date Considered	
/Zohreh Vakili/ (06/13/2007)	/Zohreh Vakili/ (06/13/2007)	

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT

	a
Atty. Docket No.: 275.0009 0101	Serial No.: 10/780,150
Applicant(s): MUNN et al.	Confirmation No.: 1273
Application Filing Date: 02/17/04	Group: 1645 1614
Information Disclosure Statement maile	d:

Examiner Initial	Copy Enclosed	Document Description	
IZVI	V	Steinman et al., "Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance," <i>Proc. Natl. Acad. Sci.</i> USA 2002;99:351-358.	
/ZV/	V	Summers et al., "Phenotypic Characterization of Five Dendritic Cell Subsets in Human Tonsils," Am. J. Pathol. 2001;159:285-295.	
IZVI	V	Sutmuller et al., "Synergism of Cytotoxic T Lymphocyte-associated Antigen 4 Blockade and Depletion of CD25 ⁺ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses," <i>J. Exp. Med.</i> , 2001;194:823-832.	
IZVI	V	Szabolcs, et al., "Dendritic Cells and Macrophages Can Mature Independently from a Human Bone Marrow-Derived, Post-Colony-Forming Unit Intermediate," <i>Blood</i> 1996;87:4520-4530.	
IZVI	>	Tafuri et al., "T Cell Awareness of Paternal Alloantigens During Pregnancy," Science, 1995;270:630-633.	
IZVI	V	Takikawa et al., "Induction of Indoleamine 2,3-Dioxygenase in tumor cells transplanted into allogeneic mouse: Interferon-γ Is the Inducer," In: Schwarcz R, ed. Kynurenine and Serotonin Pathways, NY: Plenum Press, 1991:437-444.	
IZVI	/	Tarazona et al., "Effects of different antigenic microenvironments on the course of CD8 ⁺ T cell responses in vivo," Int. Immunol., 1996;8:351-358.	
· IZVI	~	Taylor et al., "Relationship between interferon-γ, indoleamine 2,3-dioxygenase, and tryptophan catabolism," <i>FASEB Journal</i> 1991;5:2516-2522.	
· IZVI	· ·	Thomas, "IFN-γ-Mediated Antimicrobial Response," J. Immunol. 1993;150:5529-5534.	
IZVI	V	Thomas et al., "Nitric Oxide Inhibits Indoleamine 2,3-Dioxygenase Activity in Interferon-γ Primed Mononuclear Phagocytes," <i>J. Biol. Chem.</i> , 1994;269:14457-14464.	
IZVI	>	Thomas et al., "Dendritic Cells: Origin and Differentiation," Stem Cells 1996;14:196-206.	
IZVI	~	Thomas et al., "Antioxidants Inhibit Indoleamine 2,3-Dioxygenase in IFN-γ-Activated Human Macrophages: Posttranslational Regulation by Pyrrolidine Dithiocarbamate ¹ ," <i>J. Immunol.</i> , 2001;166:6332-6340.	

EXAMINER	Date Considered
/Zohreh Vakili/ (06/13/2007)	/Zohreh Vakili/ (06/13/2007)

OMB No. 0651-0011 Page 13 of 14

INFORMATION DISCLOSURE STATEMENT

Atty. Docket No.: 275.0009 0101	Serial No.: 10/780,150
Applicant(s): MUNN et al.	Confirmation No.: 1273
Application Filing Date: 02/17/04	Group: 1645 [614
Information Disclosure Statement mailed:	

Examiner Initial		
/ZV/ Trinchieri et al., "Immunoregulation 1996;59:505-511.		Trinchieri et al., "Immunoregulation by interleukin-12," J. Leukocyte Biol. 1996;59:505-511.
IZVI	~	Unanue et al., "The Basis for the Immunoregulatory Role of Macrophages and Other Accessory Cells," <i>Science</i> 1987;236:551-557.
· IZVI	•	Uyttenhove et al., "Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase", <i>Nature Medicine</i> 2003;9(10):1269-1274. Epub 2003 Sept 21.
IZVI	V	van Elsas et al., "Combination Immunotherapy of B16 Melanoma Using Anti-Cytotoxic T Luymphocyte-associated Antigen 4 (CTLA-4) and Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF)-producing Vaccines Induces Rejection of Subcutaneous and Metastic Tumors Accompanied by Autoimmune Depigmentation," J. Exp. Med. 1999;190(3):355-366.
IZVI	V	Venkateshan, "Immunocytochemical localization of the endogenous neuroexcitotoxin quinolinate in human peripheral blood monocytes/macrophages and the effect of human T-cell lymphotropic virus type I infection," <i>Proc Natl Acad Sci USA</i> , 1996;93:1636-1641.
		Vicari et al., "Reversal of Tumor-induced Dendritic Cell Paralysis by CpG Immunostimulatory Oligonucleotide and Anti-Interleukin 10 Receptor Antibody," <i>J. Exp. Med.</i> , 2002;196:541-548.
/ZV/	~	Vogelsgang, "Quinolinic Acid in Patients with Systemic Lupus Erythematosus and Neuropsychiatric Manifestations," <i>J Rheumatol.</i> , 1996;23:850-855.
. IZVI	V	Wick et al., "Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy," <i>J. Exp. Med.</i> , 1997;186:229-238.
IZVI	~	Yang et al., "Cutting Edge: Immature Dendritic Cells Generated from Monocytes in the Presence of TFG-β1 Express Functional C-C Chemokine Receptor 6 ¹ ," J. Immunol., 1999;163:1737-1741.
IZVI	V	Yang et al., "Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor," <i>J. Clin. Invest.</i> , 2003;111:727-735.

EXAMINER	Date Considered
/Zohreh Vakili/ (06/13/2007)	/Zohreh Vakili/ (06/13/2007)
	the same of the sa

INFORMATION
DISCLOSURE
STATEMENT

Atty. Docket No.: 275.0009 0101

Applicant(s): MUNN et al.

Application Filing Date: 02/17/04

Information Disclosure Statement mailed:

Serial No.: 10/780,150

Confirmation No.: 1273

Group: 1643 1614

Examiner Initial	Copy Enclosed	Document Description
IZVI	V	Yu et al., "Molecular mechanisms underlying IFN-γ-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12,". <i>Intl Immunol.</i> , 1996;8:855-865.
Induces a Potent Antitumo		Yu et al., "Combination of γ-Irradiation and Dendritic Cell Administration Induces a Potent Antitumor Response in Tumor-Bearing Mice: Approach to Treatment of Advanced Stage Cancer," Int. J. Cancer, 2001;94:825-833.
IZVI	/	Yu et al., "Cancer vaccines: progress reveals new complexities," Journ. of Clinical Investigation 2002;110:289-294.
	<u></u>	

EXAMINER	Date Considered
/Zohreh Vakili/ (06/13/2007)	/Zohreh Vakili/ (06/13/2007)

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFOR	MATION
	E SURE
STAT	EMIENT
180 00	Un E
1 115	X
STENT & T	RADER

Atty. Docket No.: 275.0009 0101	Serial No.: 10/780,150
Applicant(s): MUNN et al.	Confirmation No.: 1273
Application Filing Date: 02/17/04	Group: 1645 1614
Information Disclosure Statement mailed:	December 3, 2004

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If
	NONE					

FOREIGN PATENT DOCUMENTS

Examiner	Сору	Document Number	Date	Country	Class	Subclass	Trans	lation
Initial	Enclosed						Yes	No
<i>I</i> ZVI	~	WO 2004/094409 A1	11/04/04	PCT				
IZVI	~	WO 2004/093871 A1	11/04/04	PCT				
				10				

Examiner Initial	Document Description
	COMMONLY USED REFERENCES
	NONE
	·
·	
	·

EXAMINER	Date Considered				
/Zohreh Vakili/ (06/13/2007)	/Zohreh Vakili/ (06/13/2007)				
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

OMB No. 0651-0011 Page 1 of 1

INFORMATION
DISCLOSURE
STATEMENT

Atty. Docket No.: 275.0009 0101	Serial No.: 10/780,150
Applicant(s): MUNN et al.	Confirmation No.: 1273
Application Filing Date: 02/17/04	Group: 1645 1614
Information Disclosure Statement mailed:	May 24, 2005

U.S. PATENT DOCUMENTS

Examiner Joitlal	Copy Enclosed	Document Number	Date	Name	Cluss	Subclass	Filing Date II Appropriate
		NONE					

FOREIGN PATENT DOCUMENTS

Examiner	Сору	Document Number	Date	Country	Class	Subelass	Trans	Intion
Initial	Enclosed						Yes	No
		NONE						
1								
	1			10vL	<u> </u>	I		

Examiner Initial	Copy Reclosed	Document Description
/ZV/	•	Munn et al., Basic Aspects of Tumor Immunology "Dendritic cells (DCs) expressing indoleamine 2,3 dioxygenase (IDO) in malignancy," Basic Aspects of Tumor Immunology. Abstract No. 346, Keystone Symposium, 2003 Abstract Book, page 107, Keystone Resort, Keystone, Colorado, February 17-23, 2003

EXAMINER	Date Considered
/Zohreh Vakili/ (06/13/2007)	/Zohreh Vakili/ (06/13/2007)
*Examiner: Initial if citation considered, whether or not cit	ation is in conformance with MPEP 609: Draw line through citation if not in with part communication to applicant

OMB No. 0651-0011 Page 1 of 1

INFORMATION	Atty. Docket No.: 275.0009 0101	Serial No.: 10/780,150
DISCLOSURE	Applicant(s): MUNN et al.	Confirmation No.: 1273
STATEMENT	Application Filing Date: 02/17/04	Group: 1614
	Information Disclosure Statement mailed:	November/ <u>/</u> , 2005

U.S. PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		NONE					

FOREIGN PATENT DOCUMENTS

Examiner	Copy	Document Number	Date	Country	Class	Subclass	Trans	Lation
Initial	Enclosed						Yes	No
		NONE		·				

Examiner Initial	Copy Enclosed	Ducument Description
IZVI		Habara-Ohkubo et al., (1993) "Establishment of an Antitoxoplasma State by Stable Expression of Mouse Indoleamine 2,3-Dioxygenase," <i>Infection and Immunity</i> , Vol. 61 (5), 1810-1813
/ZV/	V	Kaufman et al. (1995) "Xenotransplantation," Annu. Rev. Immnol., Vol. 13:339-367
IZVI	~	Takikawa et al., (1990) "IFN-γ Is the Inducer of Indoleamine 2,3-Dioxygenase in Allografted Tumor Cells Undergoing Rejection," J. Immunol., Vol. 145 (4), 1246-1250
-		
<u> </u>		

EXAMINER	Datc Considered				
/Zohreh Vakili/ (06/13/2007)	/Zohreh Vakili/ (06/13/2007)				
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

OMB No. 0651-0011 Page 1 of 1

INFORMATION	Atty. Docket No.: 275.0009 0101	Serial No.: 10/780,150
DISCLOSURE	Applicant(s): MUNN et al.	Confirmation No.: 1273
STATEMENT	Application Filing Date: 02/17/04	Group: 1645 1614
	Information Disclosure Statement mailed:	December 19, 2006

U.S. PATENT DOCUMENTS

Examiner Initial	Copy Englased	Document Number	Dato	Name	Class	Subclass	Filing Date If
		NONE					
						<u> </u>	

FOREIGN PATENT DOCUMENTS

Examiner	Сору	Document Number	Oate		Country		Subclass	Translation	
initial	Enclosed_							Yes	No
/ZV/	X	2004/093871 A1	11/04/04	PCT					
				7					
				(ib)	•		1		

Evaminer Initial	Copy Enclosed	. Document Description
	4	

EXAMINER	Date Considered						
/Zohreh Vakili/ (06/13/2007)	/Zohreh Vakili/ (06/13/2007)						
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

03/20/2007 11:03 FAX 6123051228

MUETING RAASCH GEBHARDT

MAR 2'0 2007

@004

OMB No. 0651-0011

Page 1 of 1

INFORMATION	Atty. Docket No.: 275.0009 0101	Serial No.: 10/780,150		
DISCLOSURE	Applicant(s): MUNN et al.	Confirmation No.: 1273		
STATEMENT	Application Filing Date: 02/17/04	Group: 1614		
	Information Disclosure Statement mailed:	March 20, 2007		

U.S. PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	Date	Name	Class	Subclass	Filing Date If
Intoai	g.nc.iosea	NONE		·			
		·					

FOREIGN PATENT DOCUMENTS

Exeminer Initial	Copy Englosed	Document Number	Date	Country	Cluss	Subclass	Trans Yes	No No
		NONE	-					ļ
					<u></u>			

OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)

Examiner Initial	Copy Enclosed	Document Description
IZVI	Х	HOU, et al., "Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses," Cancer Res. 2007, Jan 15;67(2):792-801.
· · · · · · · · · · · · · · · · · · ·		

EXAMINER	Date Considered
/Zohreh Vakili/ (06/13/2007)	/Zohreh Vakili/ (06/13/2007)

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PAGE 4/16 * RCVD AT 3/20/2007 12:07:39 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-5/11 * DNIS:2738300 * CSID:6123051228 * DURATION (mm-ss):03-56*

INFORMATION DISCLOSURE STATEMENT MAY 0 3 2007

Atty. Docket No.: 275.0009 0101	Serial No.: 10/780,150
Applicant(s): MUNN et al.	Confirmation No.: 1273
Application Filing Date: 02/17/04	Group: 1614
Information Disclosure Statement mailed:	May 1, 2007

U.S. PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
/ZV/		4,244,946	01/13/81	Rivier et al.			
1		4,305,872	12/15/81	Johnston et al.			
		4,316,891	02/23/82	Guillemin et al.			
		4,629,784	12/16/86	Stammer			
		4,792,525	12/20/88	Ruoslahti et al.			
		4,868,116	09/19/89	Morgan et al.			<u> </u>
		4,980,286	12/25/90	Morgan et al.			<u> </u>
		5,244,807	09/14/93	Murtfeldt et al.			
		5,723,325	03/03/98	Murtfeldt et al.			
		5,874,560	02/23/99	Kawakami et al.			
		2003/0194803	10/16/03	Mellor			
		2004/0161425	08/19/04	Munn		<u></u>	
		2004/0234623	11/25/04	Munn		<u></u>	
		2005/0186289	08/25/05	Munn	-		
		2006/0292618	12/28/06	Mellor			
		2007/0048769	03/01/07	Mellor			
∇		2007/0077234 A1	04/05/07	Munn et al.			

FOREIGN PATENT DOCUMENTS

Examiner Copy Document Number		Date	Date Country		Subclass	Trans	Translation	
Initial	Enclosed						Yes	No
/ZV/	V	WO 2000/66764	11/9/00	PCT				
IZVI	~	0 385 385 A2	09/05/90	Europe				
/ZV/	~	WO 93/01286	01/21/93	PCT				

EXA	M	IN	ER
------------	---	----	----

/Zohreh Vakili/ (06/13/2007)

Date Considered

/Zohreh Vakili/ (06/13/2007)

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION
DISCLOSURE
STATEMENT

Atty. Docket No.: 275.0009 0101	Serial No.: 10/780,150	
Applicant(s): MUNN et al.	Confirmation No.: 1273	
Application Filing Date: 02/17/04	Group: 1614	
Information Disclosure Statement mailed:	May 1, 2007	

/ZV/	~	WO 1998/25840		PCT		
/ZV/	~	WO 2006/040796	10/20/06	PCT		
IZVI	~	WO 2007/000404	01/05/07	PCT		

Examiner Initial	Copy Enclosed	Document Description .
IZVI	,	Burke et al., "The role of indoleamine 2,3-dioxygenase in the anti-tumor activity of human interferon-gamma in vivo", <i>Int. J. Cancer</i> , 60(1):115-122 (1995).
IZVI	~	Cady et al., "1-Methyl-DL-tryptophan, β-(3-Benzofuranyl)-DL-alanine (the Oxygen Analog of Tryptophan), and β-[3-Benzo(b)thienyl]-DL-alanine (the Sulfur Analog of Tryptophan) Are Competitive Inhibitors for Indoleamine 2,3-Dioxygenase", Arch. Biochem. Biophys., 291(2):326-333 (1991).
IZVI	V	Gura, "Systems for Identifying New Drugs are Often Faulty," Science, 1997, 278:1041-1042.
. /ZV/	V	Habara-Ohkubo et al., "Cloning and expression of a cDNA encoding mouse indoleamine 2,3-dioxygenase", <i>Gene</i> , 105(2):221-227 (1991).
IZVI	ن	Johnson et al., "Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials," <i>British Journal of Cancer</i> , 2001, 84(10):1424-1431.
IZVI	~	Kadoya et al., "Gene structure of human indoleamine 2,3-dioxygenase," Bio. and Biophysical Research Comm. 1992, Vol.189, No. 1 pp.530-536
IZVI	~	Li et al., "Expression of indoleamine 2,3-dioxygenase in dennal fibroblasts functions as a local immunosuppressive factor," <i>J. Invest. Dermatol.</i> 2004, 122(4):953-964
IZVI		Meyer et al., "Trptophan metabolism in chronic inflammatory lung disease", <i>J. Lab. Clin. Med.</i> ,126(6):530-540 (1995).
/ZV/	~	Miki et al., Abstract # 714, "Indoleamine 2, 3- Dioxygenase Blockade Prevents Spontaneous Liver Allograft Tolerogenicity in the Mouse", <i>Transplantation</i> ®, 69(8):S297 (2000).

EXAMINER	Date Considered
/Zohreh Vakili/ (06/13/2007)	/Zohreh Vakili/ (06/13/2007)

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Atty. Docket No.: 275.0009 0101	Serial No.: 10/780,150
Applicant(s): MUNN et al.	Confirmation No.: 1273
Application Filing Date: 02/17/04	Group: 1614
Information Disclosure Statement mailed:	May 1, 2007

Examiner Initial	Copy Enclosed	Document Description
/ZV/	V	Muller et al., "Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors," <i>Expert Opinion Ther. Targets</i> , 2005, 9(4):831-849.
IZVI	>	Munn, David H., "Regulation of Macrophage Apoptosis," Grant Abstract, Grant Number 1K08HL03395-01 [online]. National Institutes of General Medical Sciences, National Institutes of Health, project dates 07/01/95-06/30/98 [retrieved on 2001-02-15]. Retrieved from the Internet: URL: http.commons.cit.nih.gov/crisp_historical/crisp_lib.getdoc?textkey=2211646&p_grant_num=1K08HL03395-01 &p_query=&ticket=63957&p_audit_session_id=363938&p_keywords=>, 2 pages.
IZVI	V	Munn, David H., "Inhibition of T Cells by Tryptophan Degradation," Grant Abstract, Grant Number 1R21AI44759-01 [online]. National Institutes of General Medical Sciences, National Institutes of Health, project dates 09/30/98-009/29/00 [retrieved on 2001-02-15]. Retrieved from the Internet: URL: http.commons.cit.nih.gov/crisp_historical/crisp_lib.getdoc?textkey=2802812&p_grant_num=1R21AI44759-01 &p_query=&ticket=63957&p_audit_session_id=363938&p_keywords=>, 2 pages.
/ZV/	~	Munn, David H., "Macrophage Mediated Immunoregulation Via Tryptophan," Grant Abstract, Grant Number 5R01HL60137-03 [online]. National Institutes of General Medical Sciences, National Institutes of Health, project dates 01/01/99-12/31/02 [retrieved on 2001-02-15]. Retrieved from the Internet: URL: http.commons.cit.nih.gov/crisp_lib.getdoc?textkey=6343616&p_query=&ticket=1890054&p_audit_session_id=3588259&p_keywords=>, 2 pages.
IZVI	~	Munn, "Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation," Curr. Opin. Immunol. 2006 Apr;18(2):220-225. Epub 2006 Feb 7.
IZVI	~	Ozaki et al., "Induction of indoleamine 2,3-dioxygenase: A mechanism of the antitumor activity of interferon γ", <i>Proc. Natl. Acad. Sci. USA</i> , 85:1242-1246 (1988).

EXAMINER	Date Considered
/Zohreh Vakili/ (06/13/2007)	/Zohreh Vakili/ (06/13/2007)

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Atty. Docket No.: 275.0009 0101	Serial No.: 10/780,150
Applicant(s): MUNN et al.	Confirmation No.: 1273
Application Filing Date: 02/17/04	Group: 1614
Information Disclosure Statement mailed:	May 1, 2007

Examiner Initial	Copy Enclosed	Document Description
IZVI	V	Peterson et al., "Evaluation of Functionalized Tryptophan Derivatives and Related Compounds as Competitive Inhibitors of Indoleamine 2,3-Dioxygenase", <i>Med. Chem. Res.</i> , 3:531-544 (1994).
/ZV/	V	Potula et al., Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis," <i>Immunobiology, Blood</i> , 1 October 2005, 106(7):233822390.
IZVI	~	Raynovich, "Late-Stage Cancer Vaccines Set to Launch, with Five Major Players, Therapeutic Vaccines Could Transform Medical Care," GEN Biobusiness Wall Street Biobeat. March 1, 2007. genengnews.com. Gen. Eng. & Biotech. News.
IZVI	~	"Rheumatoid Arthritis," Genetic Eng. & Biotech. News, March 1, 2007. Genengnews.com, (72) Translational Medicine.
IZVI	/	Romani et al., "Generation of mature dendritic cells from human blood: An improved method with special regard to clinical applicability," <i>J. Immunol. Methods</i> , 1996;196:137-151.
IZVI	V	Sarkhosh et al., "Immune cell proliferation is suppressed by the interferongamma-induced indoleamine 2,3-dioxygenase expression of fibroblasts populated in collagen gel (FPGG)," J. Cell Biochem. 2003, 1;90(1):206-217
IZVI	~	Sono et al., "Indoleamine 2,3-Dioxygenase. Equilibrium Studies of the Tryptophan Binding to the Ferric, Ferrous, and Co-Bound Enzymes", <i>J. Biol. Chem.</i> , 255(4):1339-1345 (1980).
/ZV/	~	Steckel et al., "Indoleamine 2,3-Dioxygenase expression in patients with acute graft-; versus-host disease after allogeneic stem cell transplantation and in pregnant women: association with the induction of allogeneic immune tolerance?," 2003, Scandinavian Journ. Of Immun., 57, pp 185-191
IZVI	~	Swanson et al., "CD11c+ Cells Modulate Pulmonary Immune Responses by Production of Indoleamine 2,3-Dioxygenase," 2004, Am. Journ. Of Respiratory Cell and Molecular Biology, Vol. 30, pp 311-318
/ZV/	V	Terness et al., "Inhibition of allogeneic T cell proliferation by Indoleamine 2,3-Dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites," 2002, <i>J. Exp. Med.</i> Vol.196, No. 4, pp 447-457.

EXAMINER	Date Considered
/Zohreh Vakili/ (06/13/2007)	/Zohreh Vakili/ (06/13/2007)

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.